Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study.

Abstract

Reflex sympathetic dystrophy is one of the important complications effecting the rehabilitation programmes of hemiplegic patients in a negative manner by causing pain and function loss. In this study, the aim was to investigate the effects of salmon calcitonin treatment in reflex sympathetic dystrophy that develops in hemiplegia. Forty-one patients with hemiplegia resulting from cerebrovascular events and stage 1-2 reflex sympathetic dystrophy were included in the study. Salmon calcitonin, 1 x 100 IU/day intramuscularly for 4 weeks, was administered to 25 of these patients (calcitonin group) to the other 16 patients physiological saline, 1 ml/day intramuscularly for 4 weeks, was administered (control group). At the end of the fourth week of treatment the pain score of the calcitonin group was significantly lower than that of the control group. Shoulder abduction and external rotation, wrist flexion and metacarpophalangeal extension of the calcitonin group were found to be significantly better than those of the control group. In the calcitonin group the significant decrease in pain and tenderness resulted in improvement of range of motion and motor functions.

• Authors: N Hamamci, E Dursun, C Ural, A Cakci
• Journal: The British journal of clinical practice (Br J Clin Pract) 1996 Oct-Nov Vol. 50 Issue 7 Pg. 373-5 ISSN: 0007-0947 [Print] England
• PMID: 9015909 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Analgesics
• salmon calcitonin
• Calcitonin

Topics

• Analgesics
• Calcitonin (therapeutic use)
• Hemiplegia (complications)
• Humans
• Reflex Sympathetic Dystrophy (drug therapy, etiology)